Australia markets open in 1 hour 9 minutes

Roivant Sciences Ltd. (87S.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
8.75+0.10 (+1.16%)
At close: 09:15AM CET
Full screen
Previous close8.65
Bid8.80 x N/A
Ask9.60 x N/A
Day's range8.75 - 8.75
52-week range5.93 - 12.30
Avg. volume62
Market cap7.384B
Beta (5Y monthly)1.31
PE ratio (TTM)N/A
EPS (TTM)-1.36
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

    Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG reductions similar to batoclimab in its Phase 1 studyIMVT-1402 600 mg was observed to deliver placebo-like impact on albumin and low-density lipoprotein cholesterol (LDL-C), similar to the previously disclosed 300 mg MAD cohort dataPotential best-in-class profile enables broad and exciting portfolio of indic

  • GlobeNewswire

    Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus

    Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index (SRI-4) change of 4 at Week 52Priovant plans to continue progressing the program in indications outside of Systemic Lupus Erythematosus (SLE) given the drug’s favorable safety and tolerability profile, six other positive phase 2 studies, and active arm performance in this studyPriovant expects to announce topline results from the Phase 2 POC study of brepocitinib in non-infectious uveitis (NIU)

  • GlobeNewswire

    Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update

    Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitisIMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studiesIMVT-1402 showed no statistically significant dose-rel